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Abstract
Objectives: Liver metastasis from a neuroendocrine tumour (NET) represents a significant clinical entity.
A multidisciplinary group of experts was convened to develop state-of-the-art recommendations for its
management.
Methods: Peer-reviewed published reports on intra-arterial therapies for NET hepatic metastases were
reviewed and the findings presented to a jury of peers. The therapies reviewed included transarterial
embolization (TAE), transarterial chemoembolization (TACE) and radioembolization (RE). Two systems
were used to evaluate the level of evidence in each publication: (i) the US National Cancer Institute (NCI)
system, and (ii) the GRADE system.
Results: Eighteen publications were reviewed. These comprised 11 reports on TAE or TACE and seven
on RE. Four questions posed to the panel were answered and recommendations offered.
Conclusions: Studies of moderate quality support the use of TAE, TACE and RE in hepatic metastases
of NETs. The quality and strength of the reports available do not allow any modality to be determined as
superior in terms of imaging response, symptomatic response or impact on survival. Radioembolization
may have advantages over TAE and TACE because it causes fewer side-effects and requires fewer
treatments. Based on current European Neuroendocrine Tumor Society (ENETS) Consensus Guidelines,
RE can be substituted for TAE or TACE in patients with either liver-only disease or those with limited
extrahepatic metastases.
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Introduction
The development of liver metastases from neuroendocrine
tumours (NETs) originating in the foregut, midgut or hindgut
represents a significant and frequent clinical occurrence, which
negatively impacts prognosis. The management of patients with
liver metastases can include surgical, medical, radiological and
nuclear medicine interventions.1 This broad range of possible
treatments, each of which has therapeutic potential for different
indications, necessitates evidence-based recommendations for
the optimal management of these patients. A multidisciplinary
Sources of funding: NIHR Biomedical Research Centre Oxford and the
Oxford Cancer Imaging Centre.
This paper is based on the NET-Liver-Metastases Consensus Conference,
12–13 December 2012, London, endorsed by the European–African Hepato-
Pancreato-Biliary Association (E-AHPBA), the European Neuroendocrine
Tumor Society (ENETS), the Association of Upper Gastrointestinal Sur-
geons of Great Britain and Ireland (AUGIS), the European Society of
Surgical Oncology (ESSO), the Great Britain and Ireland Hepato-Pancreato-
Biliary Association (GBIHPBA), the International Hepato-Pancreato-Biliary
Association (IHPBA) and the UK and Ireland Neuroendocrine Tumour
Society (UKINETS).
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group of experts in the management of NET patients with liver
metastases was convened in London, UK, in December 2012 to
provide updated management recommendations. The Interna-
tional Consensus Conference on NET-Liver-Mets involved 15
individual workgroup sessions that covered a variety of topics
from diagnosis to treatment. Each workgroup was comprised of
recognized experts in its particular subject matter. Prior to the
conference, questions were sent to the members of each work-
group to allow for deliberation and the development of state-
ments on the workgroup topic. During the conference, a
spokesperson for each workgroup presented the panel’s recom-
mendations and statements to the attendees and the conference
jury. Feedback on this exchange was given to the workgroup and
was considered prior to the development of the final results pre-
sented in this report. A summary of this conference has been
published recently.2
For patients who are not candidates for surgery, selective
hepatic transarterial embolization (TAE), transarterial chemoem-
bolization (TACE) or radioembolization (RE) with yttrium-90
microspheres can produce objective responses, decrease tumour
markers and control symptoms. However, none of these tech-
niques has been shown to have clear superiority over the others in
a randomized controlled trial (RCT). The authors of this manu-
script were tasked with developing recommendations on the use
of angiographic liver-directed techniques, including TAE, TACE
and RE, in relation to surgery, percutaneous liver tumour ablation
and systemic therapies.
Materials and methods
Peer-reviewed published reports on intra-arterial therapies for
NET hepatic metastases were reviewed. These were presented to a
multidisciplinary jury of peers for thorough discussion in order to
achieve consensus recommendations. The authors were asked to
consider the following questions related to percutaneous arterial
liver techniques (TAE, TACE and RE) in patients with non-
resectable NET liver metastases in conducting their review.
1 Do these techniques improve outcomes [progression-free sur-
vival (PFS), overall survival (OS) and quality of life (QoL)] in
comparison with partial (R2) resection?
2 Which of these techniques achieves the best outcome (PFS, OS,
QoL)?
3 Do these techniques improve outcomes in combination with
systemic treatment [such as peptide receptor radiotherapy
(PRRT), chemotherapy, targeted therapy, biotherapy] in com-
parison with percutaneous liver techniques alone?
4 What is the incidence of tumour dissemination during the use
of TAE, TACE or RE, evident on imaging or biopsy during
follow-up?
Selection and evaluation of reports
Multiple searches of PubMed were conducted to identify
epublished papers to December 2012 (Fig. 1). Abstracts and pres-
entations at meetings were not included in the deliberations. The
search strategy duplicated the extensive literature search
115 arƟcles idenƟfied using the keywords:
neuroendocrine; liver;
hepaƟc; metastases;
chemoembolizaƟon; embolizaƟon;
TACE; TAE; radioembolizaƟon; 
microspheres, and drug-eluƟng beads
84 arƟcles examined 
47 arƟcles
18 arƟcles included in
final analysis  
Excluding non-English, single-case
reviews, review arƟcles, case reports,
editorial, commentary arƟcles,
abstracts, posters   
Excluding heterogeneous paƟent
cohorts, repeat publicaƟons,
and studies with inadequate
and insuﬃcient data  
Applying Ɵme period of 1995 -2012 
Figure 1 Study search strategy and numbers of articles identified
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conducted by Yang et al.,3 but extended the date of publication to
December 2012 and accepted fewer articles for review. Two
systems were used to evaluate the level of evidence and strength
of endpoints of each publication: the US National Cancer Insti-
tute (NCI) medical evidence scale,4 and the GRADE (grading
of recommendations assessment, development and evaluation)
system.5
Each of the papers selected for consideration were assigned
both an NCI and a GRADE score. In addition, individual factors
derived from the GRADE system were used to estimate the
strength of the recommendations for each treatment modality
(TAE, TACE and RE). For the purposes of report evaluation by
the working group, the scoring system shown in Table 1 was
used. The NCI Levels of Evidence evaluate both the strength of
the study design and the strength of the study endpoints. The
GRADE system considers four factors to determine the strength
of a recommendation: (i) the balance between desirable and
undesirable affects; (ii) the quality of the evidence; (iii) values
and preferences, and, finally, (iv) costs. The quality of evidence is
given a ‘grade’ of A, B, C or D; thus high-quality papers receive
a GRADE score of A. The strength of the recommendation for or
against an intervention is scored as 1 if it is strong and 2 if it is
weak.
Results
A total of 18 reports met the workgroup’s stringent criteria and
were reviewed by the present authors. These included 11 reports
on TAE or TACE,6–16 and seven on RE.17–23
Radioembolization studies are outlined in Table 2. These
included four studies on the use of salvage therapy in refractory
disease and three studies conducted in mixed cohorts of patients
treated with RE as either first-line treatment or in refractory
disease. Four of these reports were retrospective studies. Studies
on TAE and TACE are outlined in Table 3. Table 4 shows GRADE
factor scoring comparisons for TAE/TACE and RE.
Do these techniques improve outcomes (PFS, OS,
QoL) in comparison with partial (R2)
surgical resection?
Because data from prospective, randomized, placebo-controlled
studies are lacking, the authors were unable to make a definitive
statement about the superiority of percutaneous arterial liver
techniques over R2 resection; neither is there sufficient evidence
to indicate the use of one technique over another in terms of PFS
or OS. There is some evidence to suggest that RE provides for
improved QoL in comparison with TAE and TACE. The review of
this literature suggests that tumour dissemination and tract
seeding are not caused by the use of arterial therapies, but by
direct puncture from ablation or biopsy (GRADE B1).
The consensus was to recommend that comparative studies
should be conducted to adequately determine whether percuta-
neous arterial liver techniques offer an advantage over R2 resec-
tion (in terms of PFS, OS and QoL). These comparative
effectiveness studies should include measures of costs, complica-
tions, QoL and hospital resource utilization. Other studies should
compare the use of embolization techniques with that of systemic
agents, and explore the utility of combinations of embolization
and systemic therapy. Higher-level evidence is required before any
strong recommendation on the use of embolotherapy and surgery
can be made.
Table 1 Conversions of the National Cancer Institute (NCI) and GRADE (grading of recommendations assessment, development and
evaluation) scoring systems4,5 used by the present working group
NCI levels of evidence GRADE GRADE
Quality score Strength score
NCI strength of study endpoints (A–D) NCI strength of study design (1–3) A = highest quality study 1 = strong
A Total mortality (or overall survival
from a defined time)
1 Randomized controlled trial
(i) Population-based, consecutive series
(ii) Consecutive cases (not population-based)
B Cause-specific mortality (or cause-specific
mortality from a defined time)
2 Non-randomized controlled trials B = high quality study 2 = weak
C Carefully assessed quality of life 3 Case series C = low quality study
(i) Population-based, consecutive series
(ii) Consecutive cases, (not population-based)
(iii) Non-consecutive cases
D Indirect surrogates D = lowest quality study
(i) Event-free survival
(ii) Disease-free survival
(iii) Progression-free survival
(iv) Tumour response rate
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Which of these techniques achieves the best
outcome (PFS, OS, QoL)?
No studies directly comparing the three forms of embolo-
therapy were discovered, nor were any found in a search of
Clinicaltrials.gov (December 2012). This is surprising because the
controversy over the relative superiority of TAE and TACE is
longstanding, yet no properly conducted prospective comparison
study has been performed. The inherent complexities of liver
embolotherapymay represent amajor barrier to investigations into
the outcomes of non-radioactive arterial therapies and to enquiries
into the use of these therapies in comparison with RE. Therefore,
no statement on which arterial therapy offers the best PFS and OS
can be made. Kalinowski et al. completed the only QoL study in
liver embolotherapy of NETs, but their study investigated only RE
and included a small sample.24However, this report,24 coupledwith
other prospective and retrospective studies,17–23 suggests the acute
toxicity profile of RE is lower than those of TAE or TACE.
Do these techniques improve outcomes in
combination with systemic treatment (such as PRRT,
chemotherapy, targeted therapy, biotherapy) in
comparison with percutaneous liver
techniques alone?
No prospective or retrospective series reported the concurrent use
of embolotherapy with PRRT, targeted systemic agents or
biotherapy. However, two RE studies involved i.v. 5-fluorouracil
(5-FU) with yttrium-90.17,19 Their results suggested somewhat
higher response rates and similar toxicity to that of RE alone, but
both were single-arm studies with small treatment groups. No
TAE/TACE studies reported the use of systemic therapy concur-
rently with liver embolotherapy. There are no comparator trials of
percutaneous liver tumour ablation and arterial embolotherapy in
hepatic metastases from NETs and therefore no statement or rec-
ommendation can be provided.
What is the incidence of tumour dissemination during
the use of TAE, TACE or RE, evident on imaging or
biopsy during follow-up?
Tumour dissemination via the direct puncture of tumour with
tract seeding is not a feature of arterial therapies. There are no
reports of such occurrences in the literature. The femoral artery is
the only site of percutaneous entry and thus no direct contact with
the tumour occurs. Conversely, locally ablative techniques and
biopsies have known potential to allow tumour dissemination.
Consensus recommendations
It is clear that higher levels of evidence are needed to refine and
optimize the treatment of NET liver metastases. The panel sug-
gests the following points should be used as a framework for
future research collaborations and for the insertion of RE into an
accepted treatment algorithm (Fig. 2).
1 Studies that compare the outcomes of the respective intra-
arterial approaches should be performed. Given the dis-
parity in post-embolization syndrome symptoms between
embolotherapy and RE, these studies should include prospec-
tive QoL measures.
2 Studies of surgical resection in comparison with intra-arterial
therapy in select patient groups should be undertaken. These
Table 2 Outcomes of studies of radioembolization in patients with liver metastases from neuroendocrine tumours
Study Patients,
n
Device used Toxicity Radiological response
(RECIST 1.0)
Survival times and rates
Rhee et al.22 42 Yttrium-90 (glass) Grade III/IV (14%) 54% Median: 22 months
Yttrium-90 (resin) 50% Median: 28 months
Kennedy et al.18 148 Yttrium-90 (resin) 33% (grade III), fatigue
(6.5%)
63% Median: 70 months
King et al.19 58 Yttrium-90 (resin)
plus 5-FU
Radiation gastritis (2
patients), duodenal ulcer
(1 patient)
39% Median: 36 months
1-, 2- and 3-year survival:
86%, 58% and 47%,
respectively
Saxena et al.23 48 Yttrium-90 (resin) 0.5% (grade III)
1 patient (biliary
obstruction)
54% Median: 35 months
1-, 2- and 3-year survival:
87%, 62% and 42%,
respectively
Cao et al.17 58 Yttrium-90 (resin)
plus 5-FU
Not reported 39.2% Median: 36 months
Paprottka et al.21 42 Yttrium-90 (resin) 0% grade III 22.5% Median: 95% at 16.2
months
Memon et al.20 40 Yttrium-90 (glass) Fatigue (63%, all grades),
nausea/vomiting (40%, all
grades), grade III, IV
(bilirubin, 8%; albumin,
2%; lymphocyte, 38%)
WHO: 64.0%; EASL: 71.4% Median: 34.4 months
1-, 2- and 3-year survival:
72.5%, 62.5%, 45.0%,
respectively
5-FU, 5-fluorouracil; EASL, European Association for the Study of the Liver; WHO, World Health Organization.
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Table 3 Outcomes of studies of transarterial embolization (TAE) and transarterial chemoembolization (TACE) in patients with liver metastases
from neuroendocrine tumours (NETs)
Study Patients,
n
Device used Toxicity Radiological
response
(RECIST 1.0)
Survival times and rates
Dong & Carr7 123 TACE Abdominal pain (44%), diarrhoea
(30%), weight loss (22%)
62% Mean: 3.3 years
3-, 5- and 10-year survival: 59%,
36% and 20%, respectively
de Baere et al.6 20 TACE with
doxorubicin
eluting beads
Nausea (61%), fever (36%) 80% Not reported
Vogl et al.16 48 TACE with
mitomycin C
Nausea and vomiting (27.8%),
abdominal pain (11.1%)
11.1% Median: 38.7 months
5 years: 11.11%
TACE with
mitomycin C +
gemcitabine
Nausea and vomiting (16.7%),
abdominal pain (10%)
23.3% Median: 57.1 months
5 years: 46.67%
Loewe et al.11 23 Bland embolization Not reported 73% Median: 69 months
1- and 5-year survival: 95.7%
and 65.4%, respectively
Eriksson et al.8 41 Bland embolization Post-embolization syndrome (all),
nausea (33%), fever (n = 7),
median hospitalization: 12 days
50% Median: 80 months
5 years: 60%
Pitt et al.13 100 Bland (n = 51)
versus TACE
(n = 49)
Bland: 7/51, (3 liver abscesses, 1
groin hematoma, 2 ileus, 1
hypotension)
TACE: none
N/A Median from diagnosis: TACE,
50.1 months; bland, 39.1
months
1-, 2- and 5-year survival: TACE,
69%, 52%, 19%, respectively;
bland, 19%, 70%, 13%,
respectively
Ruutiainen et al.15 67 Bland (n = 23)
versus TACE
(n = 44)
Grade 3 or worse toxicity in 25%
of TACE and 22% of bland
patients
TACE (≥Grade 3): pain (3); nausea
(1); GET/ALP (4); AST (1), and
infection (1)
Bland (≥Grade 3): GET/ALP (3);
AST (1), and cardiac (1)
TACE: 22%
Bland: 38%
1-, 3- and 5-year survival: TACE,
86%, 67%, 50%, respectively;
bland, 68%, 46%, 33%,
respectively
Gupta et al.10 49 TACE (n = 27)
versus bland
(n = 42)
Serious adverse events in 19
patients (8.5%), hepatorenal
syndrome (7), sepsis (6),
transient myelosuppression (1),
anasarca (1), cortical blindness
(1), necrotizing cholecystitis (1),
hepatic abscess (2)
Overall complications: TACE, 20%;
bland, 12%
TACE: 50%
Bland: 25%
Median survival for carcinoid
tumours: TACE, 33.8 months;
bland, 33.2 months; islet
tumours: TACE, 31.5 months;
bland, 18.2 months
Maire et al.12 26 TACE (n = 12)
versus bland
(n = 14)
TACE: post-embolization syndrome
(10), carcinoid crisis (2), acute
liver failure (1), neutropoenia (2)
Bland: post-embolization
syndrome (10), carcinoid crisis
(0), acute liver failure (2),
neutropoenia (0)
TACE: 100%
Bland: 92%
2-year survival: TACE, 80%;
bland, 100%
Median PFS: TACE, 19.2 months;
bland, 23.6 months
Guiu et al.9 120 NET
88 HCC
DEB-TACE in HCC
(with cirrhosis)
and NETs
(without
cirrhosis)
Liver biliary injury occurred in
64/208 patients. Occurrence
associated with DEB-TACE, P <
0.001 irrespective of tumour type
N/A N/A
Ruzniewski et al.14 23 TACE Bleeding peptic ulcer (1),
oligoanuric renal failure (1),
abdominal pain (50%), fever (6),
nausea and vomiting (5)
PR, SD, PD, TTP
61, 22, 17, 14
8/23 died at a median of 12.5
months after final TACE
ALT, alanine aminotransferase; AST, aspartate aminotransferase; DEB, drug-eluting beads; GGT, γ-glutamyl transferase; HCC, hepatocellular
carcinoma; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; TTP, time to progression.
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should investigate local control rates, but should also compare
costs, complication rates, types of complication, QoL, and out-
patient versus inpatient resource utilization.
3 Studies investigating the outcomes of intra-arterial therapy
with and without the concurrent use of systemic agents
(including biologic agents) should be conducted.
4 Studies of the outcomes of intra-arterial therapy in comparison
with those of the use of systemic agents should be conducted in
a similar fashion to that outlined in item 2.
Discussion
Neuroendocrine tumours are uncommon but are clinically chal-
lenging tumours that occur at an annual incidence of one per
100 000 people. The current ability to produce consensus guide-
lines is limited by the heterogeneity of the disease itself and of
the clinical studies recruiting patients with the disease. However,
the development of liver metastases is the factor with the worst
prognosis for patients with this disease and thus it is imperative
that some statements derived from the evidence base must be
attempted to guide clinicians in managing patients with liver
metastases from NETs. Pavel and colleagues recently published a
report on consensus guidelines for the management of liver and
other distant metastases from neuroendocrine neoplasms.1
The scope of the report is wide and touches on a great variety
of topics, which include general management options for
liver metastases. However, the current working group’s charge
differs in that the present authors were tasked with providing
Table 4 Summary of statements of GRADE quality and strength
Statement summary Quality Strength Overall
grade
1 No type of embolotherapy is most effective Moderate Strong B1
2 Embolotherapy indicated for small and large tumour burdens and hormonal symptoms Low Weak C2
3 Embolotherapy has the highest radiographic response rate Low Strong C1
4 RE is superior to TAE/TACE in QoL and side-effects profile Low Weak C2
5 By ENETS guidelines, RE is equivalent to TAE/TACE Moderate Strong B1
ENETS, European Neuroendocrine Tumor Society; QoL, quality of life; RE, radioembolization; TAE, transarterial embolization; TACE, transarterial
chemoembolization.
Morphological staging Extrahepatic spread
B. Complex pattern of LMs
(bilobar)
Non-surgical treatment
If palliation is needed If palliation is neededIf palliation is needed
Select cases Select casesAblation
(RFA, LITT)
or
TACE
TAE
90Y RE
Ablation
(RFA, LITT)
and/or
TACE
TAE
90Y RE
TACE
TAE
90Y RE
Resection
(Minor or
anatomical)
One-step surgery
Major liver resection
± RFA
(debulking)
A. Simple pattern of LMs
(unilobar or limited)
C. Diffuse LMs
Figure 2 Proposed treatment approach in liver-only metastases from neuroendocrine tumours. LITT, laser-induced thermotherapy; LMs, liver
metastases; RE, radioembolization; RFA, radiofrequency ablation; TAE, transarterial embolization; TACE, transarterial chemoembolization;
90Y, yttrium-90
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specific and detailed opinion focused on embolotherapy of liver
metastases.
Although surgical resection for metastatic NETs involving the
liver is advocated by some, no prospective randomized clinical
trials have compared the outcomes of this treatmentmodality with
those in a control group or with those of other forms of therapy. In
particular, there are limited data on which patients should be
selected for surgery. Survival data are difficult to analyse because
details on the completeness of resection, variable indications for
debulking or ‘palliative resection’ are inadequate, and follow-up
criteria are inconsistent. Complete resection (R0) rates are often
low and disease-free and overall survival rates can vary widely.
Despite this, 5-year survival rates of 46–86% have been reported
and, in general, patients in whom hepatic resection is achievable
have a better median survival and 5-year survival than those with
unresectable hepatic disease.25 Surgery has been postulated as the
only treatment to offer potential for cure,1 and favourable prog-
nostic factors include grade 1 or 2 tumours, no evidence of non-
resectable extrahepatic disease, the ability to achieve an R0
resection and the absence of carcinoid heart disease. Surgery has
been shown to have a beneficial effect in alleviating symptoms
related to the hypersecretion of serotonin or other mediators.26
Local ablation techniques have been used as sole treatments
(performed either percutaneously or laparoscopically) or in com-
bination with surgical resection. Histological proof of the com-
plete destruction of tumour foci is difficult to obtain and local
liver recurrence is common. Preferably,metastatic deposits should
measure <5 cm in diameter, although rarely larger lesions can be
targeted. Radiofrequency ablation and microwave ablation are
currently the most favoured techniques and 5-year OS rates of up
to 53% have been reported.2 Improvements in symptom control
have also been documented.27,28
Arterially directed interventional strategies provide several
diverse options in the treatment of neuroendocrine liver metas-
tases because they represent means of delivering different modali-
ties of treatment which range from arterial embolization to cause
the local ischaemia of the tumour, to the local delivery of high
doses of chemotherapy to the tumour and to selective internal
radiotherapy (SIRT) using yttrium-90 microspheres delivered via
the arterial route. The principal clinical aims of these techniques
are the reduction of hormonal symptoms in patients with func-
tionally active tumours and the control of tumour growth and
symptoms arising from tumour size.
The basis for all of the endovascular procedures discussed
herein is the discovery that neuroendocrine metastases are usually
highly vascular and that these metastases draw their blood sup-
plies predominantly from the hepatic artery rather than the portal
vein, whereas normal liver tissue acquires 70–80% of its blood
supply from the portal vein.29 An historical angle on this discovery
is provided in a recent article focusing on the pathological changes
resulting from SIRT.30 Traditionally, transarterial therapy for liver
metastases from NETs consists of TAE or TACE. In TAE,
embolization is usually performed using lipiodol, gel foam parti-
cles, polyvinyl alcohol (PVA) foam or bland microspheres. If the
artery supplying the tumour can be superselectively embolized,
the clinical benefit to be derived by devascularizing the tumour
can be achieved with a lower likelihood that a collateral blood
supply will form rapidly. In clinical cases of revascularization, TAE
or TACE can often be repeated.
Transarterial chemoembolization follows the same principles as
TAE, but the intra-arterial administration of a chemotherapeutic
agent is added at the time of embolization. This technique has the
potential to result in intra-tumoral concentrations of the drug
that are over 20 times greater than those afforded by the systemic
administration of the same drug,31 plus the potential clinical
benefit of tumour ischaemia as a result of embolization. Drugs
that are commonly used for this purpose include doxorubicin,
melphalan and streptozocin.
Selective internal radiotherapy with yttrium-90 microspheres is
a technique that has been developed to target multiple sites of
disease within the liver as a form of arterially delivered
brachytherapy. By contrast with surgical resection and
radiofrequency ablation or other forms of local ablation, the
number and sites of liver metastases do not limit its use. The
technique of SIRT involves an outpatient procedure in which a
transfemoral catheterization is performed and millions of radio-
active microspheres (15–20 million if resin; 1–8 million if glass)
are selectively released into the hepatic arterial supply under
fluoroscopic guidance. This treatment preferentially delivers a
high dose of radiation to the liver tumour while sparing much of
the normal liver.
Bearing in mind the heterogeneity of this disease and the diffi-
culty of defining cohorts of patients with the same pathological
classification of disease, rates of symptomatic response to TAE,
TACE and SIRT in the studies reviewed in the present paper would
appear to be 39–95% within a time period of 1–18 months from
treatment. In other words, the majority of patients do experience
improvements in hormonal syndromes and the symptoms caused
by the disease burden. The clinical side-effects of the procedures
include fever, leukocytosis, abdominal pain and elevated liver
enzyme levels. More severe complications include pleural effu-
sion, bowel ischaemia, hepatic infarction, liver abscess and
radiation-induced liver disease (SIRT only, significantly <2% of
cases treated). As the occurrence of severe side-effects is uncom-
mon, most patients who are offered intra-arterial therapies for
symptom relief consent to treatment and appreciate some degree
of clinical benefit.
In advocating for greater research into the use and outcomes
of intra-arterial therapies for metastatic NET carcinomas, the
present group emphasizes the importance of applying robust entry
criteria (which should include a central histology review of all
cases), of optimizing recruitment by conducting multicentre trials
and ensuring adequate quality assurance of treatment across par-
ticipating centres, and of considering the evolution of the standard
of care during the recruitment and follow-up phases of clinical
trials. For relatively rare tumours such as NETs, there may be value
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in planning for combined analyses of the outcomes of several trials
in order to facilitate greater statistical power. For example,
FOXFIRE and SIRFLOX are both randomized multicentre trials
with participating centres in Australia, New Zealand, Europe and
the USA, which have evaluated the addition of yttrium-90 resin
microspheres to first-line chemotherapy in patients with non-
resectable liver metastases from colorectal cancer (P. Gibbs et al.
2014, unpublished data).32 Both trials use similar chemotherapy
delivery regimens with regard to the sequencing of drugs and the
intra-arterial treatment intervention. Discussion between the
respective development groups of the two trials led to the formu-
lation of similar protocols and treatment paradigms in order to
facilitate sufficient power for the prospective combined analysis of
OS (P. Gibbs et al. 2014, unpublished data).32
There are ongoing controversies over the feasibility of OS studies
(treatment crossover) as well as the clinical correlation between
imaging responses and the manifestation of symptoms in metas-
tases from NETs. Accordingly, the use of QoL becomes of signifi-
cant interest. Although its use is still controversial, the European
Organization for Research and Treatment of Cancer (EORTC)
QLQ-GINET21 tool would strengthen any study of metastases
from NETs and should be considered an essential component of
prospective trials. The incorporation of such a tool is relevant not
only to patients with mild symptoms (flushing), but also to those
afflicted by themore severe and debilitating symptoms (diarrhoea,
shortness of breath).33,34 These are currently being studied in pro-
spective settings (NCT00815620, NCT00454376). Overall survival
cannot be used as in other cancers because life expectancy is long
and multiple treatment lines are available. Quality of life is not
sensitive enough and is not affected by treatment in most RCTs.
Symptomatic response, including hormone-related symptoms, is
observed in 80–90% of patients, and radiological response accord-
ing to RECIST (response evaluation criteria in solid tumours) in
30–50%. Although no clear correlation between these two param-
eters has yet been established, radiological response is almost
always associated with the alleviation of symptoms.
It is fortunate that multiple treatment options for the liver-
directed therapy of hepatic metastases from NETs are available. It
is now the responsibility of this field to learn the optimal ways of
employing local therapies to achieve the best possible QoL in
patients, sustainable resource utilization, and enhanced sequenc-
ing of treatment with new systemic and biologic agents that show
encouraging promise in the treatment of liver metastases from
NETs.
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